Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-09-18

Clinical Trial Update: Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients [Phase 2]

View source ↗

Summary

Phase 2 trial of IBI-10090 in ocular inflammation associated with cataract surgery was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IBI-10090 (IBI-10090)

Snippet

Sponsor: ICON Bioscience Inc | Conditions: Ocular Inflammation | Phase 2 | Status: TERMINATED | Results posted: 2013-09-18